The primary goal of the trial was met with improvement in atopic dermatitis on the hands post 16 weeks of tralokinumab treatment versus the placebo. Credit: Ladanifer / Shutterstock. LEO Pharma has ...

The study plans to enrol up to 12 patients. Credit: Chinnapong / Shutterstock.com. Kenai Therapeutics has dosed the first patient in its multi-centre Phase I REPLACE trial evaluating the allogeneic ...

The approval follows a review of updated clinical documentations, including the investigator brochure, amended protocol, and information from the participants. Credit: mojo cp/Shutterstock.com.

Eli Lilly has now submitted a new drug application (NDA) for GLP-1RA orforglipron to the FDA for use in adults with obesity.

Recently, artificial intelligence (AI) has been paving the way and helping sponsors with patient identification and participant retention. Digital twins, a new technological frontier in the AI space, ...

An expert from a CRO-SMO discusses Japan’s advantages as a clinical trial site. Credit: Athanasios Psimadis / Arena International Events. “Japan has the second biggest market for branded drugs and is ...

The trial will enrol 300 chronic low back pain patients with inflammatory degenerative disc disease of less than five years duration. Credit: Anatoliy Cherkas / Shutterstock. Australia-based Mesoblast ...

AI technology in clinical trials has the potential to speed up cohort selection and patient recruitment. However, data management and inherit bias in datasets need to be addressed first.

In 2018, roughly a year before the World Health Organization declared Covid-19 a global health emergency, a conference in Edinburgh imagined a very different type of medical crisis: during a ...

Alternative trial designs are used more commonly in cell and gene therapy trials where it can be difficult to use a traditional randomised clinical trial model. Image credit: Getty Images / Suppachok ...

The clinical trial sector reflects on what it believes will be the biggest difficulties of 2025. Image credit: Shutterstock / 3rdtimeluckystudio It has been a turbulent time for the pharmaceutical ...

Novartis announced the termination in its Q2 2025 earnings. Image credit: Melnikov Dmitriy / Shutterstock.com. Novartis is stopping the development of ianalumab in hidradenitis suppurativa (HS) after ...